Form 4: Johnson & Johnson Reports Changes in Beneficial Ownership of CVRx, Inc. Shares

Johnson & Johnson reports transactions involving CVRx, Inc. common stock and derivative securities, including warrant exercises and stock option acquisitions, through its subsidiary Johnson & Johnson Innovation JJDC, Inc.

Summary

• Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation JJDC, Inc. (JJDC), reported changes in its beneficial ownership of CVRx, Inc. common stock.
• On February 16, 2024, JJDC exercised a warrant to purchase 607,725 shares of CVRx common stock at a price of $0.158 per share.
• The warrant exercise was executed on a cashless basis, resulting in the withholding of 3,725 shares to cover the exercise price, with the remaining 604,000 shares issued to JJDC.
• On February 16, 2024, JJDC sold 3,725 shares at $25.81.
• On February 29, 2024, JJDC acquired stock options at a price of $0.237, $1.186, $3.955 and $5.141.
• JJDC indirectly beneficially owns 4,103,430 shares of CVRx common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The transactions indicate continued investment by Johnson & Johnson in CVRx, which is generally a positive signal. However, it's a routine filing, so the impact is moderate.

Positives

• The exercise of the warrant by Johnson & Johnson indicates a continued investment in CVRx, Inc.

Industry Context

This filing reflects ongoing investment activity by a major player (Johnson & Johnson) in a smaller medical device company (CVRx), which is typical in the healthcare industry where larger companies often invest in or acquire innovative smaller firms.

Comparison to Industry Standards

• Johnson & Johnson's investment strategy through JJDC is comparable to other large pharmaceutical and medical device companies that have venture capital arms or dedicated investment subsidiaries.
• These entities often take minority stakes in promising companies to gain exposure to new technologies and potential acquisition targets.
• The size of the warrant exercise and stock option acquisitions are within the typical range for such investments in the medical device sector.

Stakeholder Impact

• The transactions may have a slightly positive impact on CVRx shareholders due to the continued investment by Johnson & Johnson.
• The investment could potentially benefit CVRx employees through increased job security and growth opportunities.

Key Dates